PREVALÊNCIA DE DOENÇA RENAL CRÔNICA EM PACIENTES HIV-POSITIVO ACOMPANHADOS NO HC-UFPR
Resumo
Objetivo: Avaliar a prevalência de DRC em pacientes portadores de HIV em acompanhamento no ambulatório de infectologia em um Hospital Universitário de Curitiba. Métodos: Estudo transversal retrospectivo com análise de 396 prontuários de pacientes portadores de HIV entre 20 e 50 anos de idade acompanhados no ambulatório de Infectologia do Hospital de Clínicas da Universidade Federal do Paraná (HC-UFPR) no ano de 2013. Resultados: Foram encontrados 9 pacientes (2,3%) com ritmo de filtração glomerular estimado (RFGe) < 60 mL/min/1,73 m2 nas duas avaliações. Dos 108 pacientes que possuíam duas avaliações de proteinúria, 6 pacientes (1,5% do total) apresentavam proteinúria persistente. Dessa forma, 14 (3,5%) preencheram o critério diagnóstico para DRC. Entre os 194 pacientes (48,9%) que possuíam apenas uma avaliação de proteinúria, cerca de 44 pacientes (11,1% do total) apresentavam algum grau de proteinúria. Hipertensão arterial (p<0,0001) e dislipidemia (p=0,026) foram significativamente mais prevalentes nos pacientes com DRC. Além disso, houve uma correlação negativa e significativa entre RFGe e idade (r=-0,48; p<0,0001); tempo de tratamento com TARV (r=-0,12; p=0,04) e tempo de diagnóstico do HIV (r=-0,15; p=0,004). Finalmente, uma correlação positiva e significativa foi encontrada entre RFGe e CD4+ nadir (r=0,10; p=0,04). Conclusão: Na amostra estudada foi encontrada uma prevalência de DRC de 3,5%, sendo que pacientes portadores de HIV com menores valores de CD4+ nadir e maior tempo de tratamento e de doença parecem apresentar um risco maior de desenvolver DRC.
Palavras-chave
Texto completo:
PDFReferências
Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, Monforte A d’Arminio, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet [Internet]. 2003 Jul [cited 2015 Oct 8];362(9377):22–9. Available from: http://www.sciencedirect.com/science/article/pii/S0140673603138020
Redington AN, Gardiner H, Fisk NM. Survival after introduction of HAART in people with known duration of HIV-1 infection. The CASCADE Collaboration. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet. 2000;355:1158–9.
Gonzalez MA, Martin L, Munoz S, Jacobson JO. Patterns, trends and sex differences in HIV/AIDS reported mortality in Latin American countries: 1996-2007. BMC Public Health [Internet]. 2011 Jan [cited 2015 Oct 8];11:605. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3173348&tool=pmcentrez&rendertype=abstract
Palella FJ, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43(1):27–34.
Schwartz EJ, Szczech LA, Ross MJ, Klotman ME, Winston JA, Klotman PE. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol [Internet]. 2005 Aug 1 [cited 2015 Oct 8];16(8):2412–20. Available from: http://jasn.asnjournals.org/content/16/8/2412.abstract
Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis. BMC Public Health [Internet]. 2012 Jan [cited 2015 Oct 8];12:234. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3402981&tool=pmcentrez&rendertype=abstract
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3:1–150.
Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet (London, England) [Internet]. 2005 Jan [cited 2015 Aug 26];365(9456):331–40. Available from: http://www.sciencedirect.com/science/article/pii/S0140673605177897
Ando M, Tsuchiya K, Nitta K. How to manage HIV-infected patients with chronic kidney disease in the HAART era. Clin Exp Nephrol [Internet]. 2012 Feb 1 [cited 2015 Oct 8];16(3):363–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22294158
Kalyesubula R, Perazella MA. Nephrotoxicity of HAART. AIDS Res Treat [Internet]. 2011 Jan [cited 2015 Aug 31];2011:562790. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3157198&tool=pmcentrez&rendertype=abstract
Falutz J. Therapy Insight: body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy. Nat Clin Pract Endocrinol Metab [Internet]. Nature Publishing Group; 2007 Sep [cited 2015 Oct 8];3(9):651–61. Available from: http://dx.doi.org/10.1038/ncpendmet0587
Daugas E, Rougier JP, Hill G. HAART-related nephropathies in HIV-infected patients. Kidney Int. 2005;67(2):393–403.
Jao J, Wyatt CM. Antiretroviral Medications: Adverse Effects on the Kidney. Adv Chronic Kidney Dis [Internet]. Elsevier Ltd; 2010;17(1):72–82. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1548559509001335
Castro KG, Ward JW, Slutsker L, Buehler JW, Jaffe HW, Berkelman RL, et al. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mortal Wkly Report, Natl Cent Infect Dis Div HIV/AIDS, Centers Dis Control Prev [Internet]. 1992;41(RR-17):1–19. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8093740
Aguiree F, Brown A, Cho NH, Dahlquist G, Dodd S, Dunning T, Hirst M, Hwang C, Magliano D, Patterson C, Scott C, Shaw J, Soltesz G, Usher-Smith J WD. IDF Diabetes Atlas: sixth edition. Basel, Switzerland: International Diabetes Federation. 2013.
Sociedade Brasileira de Cardiologia. V DIRETRIZ BRASILEIRA DE DISLIPIDEMIAS E PREVENÇÃO. Arq Bras Cardiol. 2013;101.
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. Evidence-Based Guideline for the Management of High Blood Pressure in Adults. Jama [Internet]. 2013;1097(5):1–14. Available from: http://jama.jamanetwork.com/article.aspx?articleid=1791497nhttp://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2013.284427
Mocroft A, Kirk O, Gatell J, Reiss P, Gargalianos P, Zilmer K, et al. Chronic renal failure among HIV-1-infected patients. AIDS [Internet]. 2007;21(December 2006):1119–27. Available from: http://discovery.ucl.ac.uk/164321/
Gupta SK, Mamlin BW, Johnson CS, Dollins MD, Topf JM, Dubé MP. Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients. Clin Nephrol [Internet]. 2004 Jan [cited 2015 Oct 8];61(1):1–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14964451
Wyatt CM, Winston JA, Malvestutto CD, Fishbein DA, Barash I, Cohen AJ, et al. Chronic kidney disease in HIV infection: an urban epidemic. Aids [Internet]. 2007;21:2101–3. Available from: http://journals.lww.com/aidsonline/Abstract/2007/10010/Chronic_kidney_disease_in_HIV_infection__an_urban.13.aspx
Centro de Epidemiologia, Coordenação de Vigilância Epidemiológica, Coordenação Municipal de DST/HIV/AIDS/Hepatites Virais. Boletim Epidemiológico: Curitiba-CE-CVE. Curitiba; 2014. p. 32.
Tannock L. Dyslipidemia in Chronic Kidney Disease [Internet]. MDText.com, Inc.; 2015 [cited 2015 Oct 18]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK305899/
Da Cunha J, Maselli LM, Stern AC, Spada AC, Spada C, Bydlowski SP. Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs. World Journal of Virology [Internet]. 2015;4(2):56-77. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25964872
DOI: http://dx.doi.org/10.5380/rmu.v4i4.50646
DOI (PDF): http://dx.doi.org/10.5380/rmu.v4i4.50646.g31704
Apontamentos
- Não há apontamentos.
